Skip to main content

XDx to Restructure, Cut 25 Jobs

NEW YORK (GenomeWeb News) – Molecular diagnostics firm XDx is restructuring its business, which will include cutting 25 jobs, the Brisbane, Calif.-based firm said today.
 
XDx said that it is shifting its priorities to efforts that will increase research, development, and commercial activities in support of its AlloMap test for management of heart transplant patients. The firm intends to continue “selected activities” in autoimmunity.
 
AlloMap is a multi-gene molecular expression test that is used in conjunction with standard clinical assessment to aid physicians in identifying heart transplant recipients with stable allograft function who have a low probability of moderate to severe acute cellular rejection at the time of testing.
 
The test was cleared for marketing by the US Food and Drug Administration in August. The firm said that it has been used on more than 5,000 patients at more than 70 centers in the US since its introduction as a CLIA-waived test in 2005.
 
XDx said that it would focus on maximizing the market potential for AlloMap while restructuring its internal development programs and pursuing external collaborations in lupus research. It also said it will suspend its development activities for a lung transplant testing product.
 
In addition to cutting 25 jobs, XDx said that it would undertake “other cost-saving measures” that are expected to speed the firm’s path to profitability. It did not provide further details regarding those other measures.
 
Before the cuts, XDx had 111 employees. The firm said that the cuts would come mostly in its R&D operations.
 
XDx had filed to go public last year, but it pulled the IPO in September, citing “current public market conditions.”
 
 

The Scan

UK Funds to Stay Ahead of Variants

The UK has announced a further £29.3 million to stay on top of SARS-CoV-2 variants, the Guardian reports.

Push for Access

In a letter, researchers in India seek easier access to COVID-19 data, Science reports.

Not as Cold

Late-stage trial results are expected soon for an RNA-based vaccine that could help meet global demand as it does not require very cold storage, the New York Times writes.

Genome Research Papers on Microbes' Effects on Host Transfer RNA, Honeybee Evolution, Single-Cell Histones

In Genome Research this week: influence of microbes on transfer RNA patterns, evolutionary relationships of honeybees, and more.